Difference between revisions of "Paclitaxel (Taxol)"

Revision as of 12:21, 26 May 2022

General information

Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.^[1]^[2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is established (work in progress)

Non-small cell lung cancer
- Non-small cell lung cancer, nonsquamous
- Non-small cell lung cancer, squamous

Diseases for which it is used

Patient drug information

History of changes in FDA indication

12/29/1992: Initial FDA approval for treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy
4/9/1998 (earliest label available on Drugs @ FDA): Indicated for:

First-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Taxol is indicated in combination with cisplatin.
The treatment of breast cancer after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
The second-line treatment of AIDS-related Kaposi's sarcoma.

6/30/1998: New indication added: in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
10/25/1999: New indication for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.

Also known as

Brand names:

Synonyms
Abitaxel	Altaxel	Anzatax	Anzatec	Asotax	Betaxel	Bristaxol	Britaxol
Clitaxel	Cytax	Daburex	Dalys	Drifen	Ebetaxel	Formoxol	Genexol
Genetaxyl	Gros	Ifaxol	Intaxel	Magytax	Medixel	Mitotax	Neotacs
Neotaxan	Neotaxl	Ofoxel	Oncotaxel	Onxol	Paclitax	Paclitaxin	Pacliteva
Pacxel	Padexol	Paklitaxfil	Panataxel	Parexel	Paxene	Paxenor	Paxus
Petaxel	Phyxol	Poltaxel	Praxel	Ribotax	Sindaxel	Taclipaxol	Tarvexol
Taxocris	Taxodiol	Taxol	Taxomedac	Taycovit	Unitaxel	Yewtaxan

References

[insert-1] 1.0 ^1.1 ^1.2 Paclitaxel (Taxol) package insert

[2] Paclitaxel (Taxol) package insert (locally hosted backup)

[3] Paclitaxel (Taxol) patient drug information (Chemocare)

[4] Paclitaxel (Taxol) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 6: / Line 6: @@
 For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
-==Diseases for which it is established==
+==Diseases for which it is established ''(work in progress)''==
 *[[Non-small cell lung cancer]]
 **[[Non-small cell lung cancer, nonsquamous]]